Advanced Micro Devices vs Heron Therapeutics Inc — how do they compare? Advanced Micro Devices trades at $473.42 (market cap $766.54B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Advanced Micro Devices is far larger — about 12088.6× Heron Therapeutics Inc's market cap, and Advanced Micro Devices is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AMD | HRTX | |
|---|---|---|
Market Cap | $766.54B | $63.41M |
Sector | Technology | Health |
52-Week High | $580.91 | $1.49 |
52-Week Low | $151.14 | $0.33 |
Enterprise Value | $757.71B | $161.31M |
Signals from Pluang's Aura AI — not financial advice
AMD trades at $483.36, down 1.21% on the day, near its pivot point of $487 with support at $473 and resistance at $497. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $1.66 versus $1.62 expected, and revenue growth accelerating to $34.64 billion in 2025 from $25.8 billion in 2024. Operating cash flow surged to $7.71 billion in 2025, supporting investments in AI and data center segments. Technical indicators are neutral overall, with RSI levels suggesting balanced momentum.
Outlook remains positive driven by AI demand and market share gains, but high valuation multiples pose risks. Analyst consensus is bullish with a $615.11 price target, though competition and execution challenges warrant caution. The stock offers growth exposure but requires monitoring of competitive dynamics and margin sustainability.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →